<DOC>
	<DOCNO>NCT01203306</DOCNO>
	<brief_summary>Well differentiate neuroendocrine ( NE ) carcinomas low proliferative activity conventional chemotherapy recommend . Metronomic chemotherapy , i.e . frequent administration cytotoxic drug low dos , demonstrate antiangiogenetic property . Since well differentiate NE carcinomas highly vascular , rationale test metronomic chemotherapy antiangiogenetic drug . This national , multicenter , phase II study .</brief_summary>
	<brief_title>Bevacizumab Plus Somatostatin Analogue Metronomic Capecitabine Patients With Advanced Neuroendocrine Tumors</brief_title>
	<detailed_description>Metastatic locally advance well differentiate neuroendocrine carcinoma treat combination bevacizumab ( 5 mg/kg ) plus octreotide LAR ( long- act release ) 20/30 mg plus capecitabine administer metronomic schedule ( 2000 mg/day ) . Patients stable disease , complete partial response continue treatment progressive disease unacceptable toxicity . Primary endpoint : response treatment , evaluate accord RECIST criterion . Secondary endpoint : - toxicity , grade accord NCI-CTG criterion ; - symptomatic response : evaluate accord change frequency intensity symptom ; - biochemical response : evaluate consider change tumor marker level ( circulate Chromogranin A ) ; - relationship vascular endothelial growth factor ( VEGF ) polymorphisms response treatment ; - time progression survival : measured date treatment start date progression date last follow-up death , respectively .</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Histologically cytologically diagnosis welldifferentiated neuroendocrine carcinoma Inoperable disease Age &gt; 18 ECOG Performance Status 02 Life expectancy least 12 week Measurable and/or evaluable lesion accord RECIST criterion Radiological documentation disease progression Adequate bone marrow reserve Adequate hepatic renal function Urine dipstick proteinuria &lt; 2+ Written inform consent Comply protocol procedure Exclusion criterion : Serious nonhealing wound ulcer Evidence bleed diathesis coagulopathy Uncontrolled hypertension Clinically significant cardiovascular disease example cerebrovascular accident ( ≤6 month ) , myocardial infarction ( ≤6 month ) , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication Current recent ongoing treatment anticoagulant therapeutic purpose Chronic , daily treatment highdose aspirin ( &gt; 325 mg/day ) medication know predispose gastrointestinal ulceration Patients severe renal impairment ( creatinine clearance 30 ml/min ) Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study treatment start , anticipation need major surgical procedure course study Pregnant lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>somatostatin analogue</keyword>
	<keyword>metronomic capecitabine</keyword>
	<keyword>neuroendocrine tumor</keyword>
</DOC>